D.E. Shaw & Co’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-243,976
| Closed | -$3.69M | – | 5508 |
|
|
2022
Q3 | $3.69M | Sell |
243,976
-4,423
| -2% | -$51.4K | ﹤0.01% | 2412 |
|
|
2022
Q2 | $1.86M | Buy |
248,399
+187,899
| +311% | +$1.32M | ﹤0.01% | 3137 |
|
|
2022
Q1 | $551K | Buy |
+60,500
| New | +$466K | ﹤0.01% | 4309 |
|
|
2021
Q3 | – | Sell |
-21,456
| Closed | -$344K | – | 5484 |
|
|
2021
Q2 | $344K | Buy |
+21,456
| New | +$368K | ﹤0.01% | 4207 |
|
|
2020
Q1 | – | Sell |
-9,438
| Closed | -$228K | – | 4377 |
|
|
2019
Q4 | $228K | Sell |
9,438
-137,331
| -94% | -$2.84M | ﹤0.01% | 3753 |
|
|
2019
Q3 | $2.82M | Buy |
+146,769
| New | +$3.36M | ﹤0.01% | 2098 |
|
|
2017
Q2 | – | Sell |
-5,508
| Closed | -$250K | – | 3596 |
|
|
2017
Q1 | $250K | Buy |
+5,508
| New | +$246K | ﹤0.01% | 3041 |
|
|
2016
Q4 | – | Sell |
-121,896
| Closed | -$4.6M | – | 3664 |
|
|
2016
Q3 | $4.6M | Buy |
121,896
+22,445
| +23% | +$495K | 0.01% | 1347 |
|
|
2016
Q2 | $1.75M | Buy |
+99,451
| New | +$1.61M | ﹤0.01% | 2027 |
|
|
2016
Q1 | – | Sell |
-26,833
| Closed | -$653K | – | 3873 |
|
|
2015
Q4 | $653K | Sell |
26,833
-19,356
| -42% | -$452K | ﹤0.01% | 2914 |
|
|
2015
Q3 | $819K | Buy |
46,189
+23,389
| +103% | +$424K | ﹤0.01% | 2737 |
|
|
2015
Q2 | $402K | Buy |
+22,800
| New | +$418K | ﹤0.01% | 3271 |
|
D.E. Shaw & Co's AERI Position: Q4 2022 in Review
D.E. Shaw & Co sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 243,976 shares — an estimated $3.69M sold.
D.E. Shaw & Co first reported a position in AERI in Q2 2015 and held it in 12 quarters. The position peaked at $4.6M in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- D.E. Shaw & Co reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- D.E. Shaw & Co sold 243,976 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.69M.
- D.E. Shaw & Co first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 12 quarters.
- D.E. Shaw & Co's Aerie Pharmaceuticals position peaked at $4.6M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.